Up to 40 percent of women currently undergoing unnecessary procedures for cervical disease diagnosis could avoid the psychological and financial burdens and the potential for medical complications from treatment if given a non-invasive test with the LuViva® Advanced...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it has entered into definitive agreements with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock....
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced its operating results for the first quarter ended March 31, 2013. Revenue and other income for the first quarter of 2013 was approximately $374,000, including $132,000 in sales of LuViva® devices...
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its first quarter ended March 31,...
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) today announced that multi-center, clinical trial results for the LuViva® Advanced Cervical Scan are set to be published in an upcoming issue of Gynecologic Oncology, the official publication of the Society of...
